Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives

Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (SOC) regimens. Future therapeutic drugs were...

Descripción completa

Detalles Bibliográficos
Autores principales: Chae, Hee Bok, Park, Seon Mee, Youn, Sei Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687480/
https://www.ncbi.nlm.nih.gov/pubmed/23844410
http://dx.doi.org/10.1155/2013/704912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687480/
https://www.ncbi.nlm.nih.gov/pubmed/23844410
http://dx.doi.org/10.1155/2013/704912

Ejemplares similares